CorMedix announces U.S. inpatient availability of DefenCath

CorMedix announced DefenCath catheter lock solution is now commercially available for U.S. inpatient use. DefenCath is approved by the U.S. Food and Drug Administration to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. Joseph Todisco, Chief Executive Officer of CorMedix commented, “Today opens a new chapter for healthcare providers, offering them an opportunity to reduce the risk of CRBSIs in a patient population already vulnerable due to underlying kidney failure. We are proud to provide an option for adult patients who face the risk of CRBSIs. We look forward to expanding the availability of DefenCath to the outpatient setting later this year.”